141 related articles for article (PubMed ID: 37218572)
21. [A Case of HER2 Positive Occult Breast Cancer Presenting as Swollen Axillary Lymph Nodes].
Ishiba T; Oda G; Nakagawa T; Akashi T; Yamashita Y; Aburatani T; Ogo T; Nakashima Y; Baba H; Hoshino N; Nishioka Y; Kawano T
Gan To Kagaku Ryoho; 2018 Mar; 45(3):533-535. PubMed ID: 29650929
[TBL] [Abstract][Full Text] [Related]
22. A rare case of isolated adrenal metastasis of invasive ductal breast carcinoma.
Andjelić-Dekić N; Božović-Spasojević I; Milošević S; Matijašević M; Karadžić K
Srp Arh Celok Lek; 2014; 142(9-10):597-601. PubMed ID: 25518541
[TBL] [Abstract][Full Text] [Related]
23. [Stage Ⅳ HER2-Positive Breast Cancer That Showed Complete Response for Over One Year after Discontinuation of Anti-HER2 Therapy-A Case Report].
Terakawa H; Ogaito T; Okamoto K; Shima S; Terasaki K; Tanaka H; Hashimoto M; Zaimoku R; Takei R; Terada I; Tsukioka Y; Kiriyama M
Gan To Kagaku Ryoho; 2021 Dec; 48(13):1559-1560. PubMed ID: 35046255
[TBL] [Abstract][Full Text] [Related]
24. Antemortem diagnosis of pulmonary tumor thrombotic microangiopathy in a patient with recurrent breast cancer: a case report.
Takahashi Y; Uruga H; Fujii T; Mochizuki S; Hanada S; Takaya H; Miyamoto A; Morokawa N; Kurosaki A; Kishi K
BMC Cancer; 2016 Aug; 16(1):666. PubMed ID: 27549622
[TBL] [Abstract][Full Text] [Related]
25. Axillary lymph node metastasis as the first manifestation of male occult breast cancer: A Case Report.
Wang X; Fan L; Yan W; Zhang Q; Bao S; Wang Y; Bao X; Liu L
Medicine (Baltimore); 2018 Dec; 97(50):e13706. PubMed ID: 30558087
[TBL] [Abstract][Full Text] [Related]
26. Molecular portraits and trastuzumab responsiveness of estrogen receptor-positive, progesterone receptor-positive, and HER2-positive breast cancer.
Zhao S; Liu XY; Jin X; Ma D; Xiao Y; Shao ZM; Jiang YZ
Theranostics; 2019; 9(17):4935-4945. PubMed ID: 31410192
[No Abstract] [Full Text] [Related]
27. The importance of tissue confirmation of metastatic disease in patients with breast cancer: lesson from a brain metastasis case.
Ding J; Hu P; Chen J; Wu X; Cao Y
Oncoscience; 2016; 3(9-10):268-274. PubMed ID: 28050577
[TBL] [Abstract][Full Text] [Related]
28. Clinical characteristics and disease outcomes in ER+ breast cancer: a comparison between HER2+ patients treated with trastuzumab and HER2- patients.
Li S; Wu J; Huang O; He J; Zhu L; Chen W; Li Y; Chen X; Shen K
BMC Cancer; 2021 Jul; 21(1):807. PubMed ID: 34256710
[TBL] [Abstract][Full Text] [Related]
29. Axillary response according to neoadjuvant single or dual human epidermal growth factor receptor 2 (HER2) blockade in clinically node-positive, HER2-positive breast cancer.
Cha C; Ahn SG; Kim D; Lee J; Park S; Bae SJ; Kim JY; Park HS; Park S; Kim SI; Park BW; Jeong J
Int J Cancer; 2021 Oct; 149(8):1585-1592. PubMed ID: 34213778
[TBL] [Abstract][Full Text] [Related]
30. A Locally Advanced Breast Cancer that Achieved pCR with Pertuzumab, Trastuzumab and Docetaxel: Case Report.
Inoue Y; Yamashita N; Tokunaga E; Tanaka K; Ueo H; Saeki H; Oki E; Yamamoto H; Maehara Y
Anticancer Res; 2017 Apr; 37(4):1917-1921. PubMed ID: 28373460
[TBL] [Abstract][Full Text] [Related]
31. Assessment of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) status in the fine needle aspirates of metastatic breast carcinomas.
Monaco SE; Wu Y; Teot LA; Cai G
Diagn Cytopathol; 2013 Apr; 41(4):308-15. PubMed ID: 22045649
[TBL] [Abstract][Full Text] [Related]
32. Estrogen receptor (ER), progesterone receptor (PR), and HER2 expression pre- and post- neoadjuvant chemotherapy in primary breast carcinoma: a single institutional experience.
Kinsella MD; Nassar A; Siddiqui MT; Cohen C
Int J Clin Exp Pathol; 2012; 5(6):530-6. PubMed ID: 22949935
[TBL] [Abstract][Full Text] [Related]
33. Hormone receptor and HER2 assessment in breast carcinoma metastatic to bone: A comparison between FNA cell blocks and decalcified core needle biopsies.
Zeng J; Piscuoglio S; Aggarwal G; Magda J; Friedlander MA; Murray M; Akram M; Reis-Filho JS; Weigelt B; Edelweiss M
Cancer Cytopathol; 2020 Feb; 128(2):133-145. PubMed ID: 31883437
[TBL] [Abstract][Full Text] [Related]
34. Trastuzumab combined with doublet or single-agent chemotherapy as first-line therapy for HER2-positive metastatic breast cancer.
Yu YF; Wang Y; Fu TP; Chen K; Liu JQ; Yao HR
Breast Cancer Res Treat; 2018 Apr; 168(2):337-348. PubMed ID: 29188398
[TBL] [Abstract][Full Text] [Related]
35. Single-dose trastuzumab monotherapy achieved pathological complete response (pCR) in a patient with HER2-positive breast cancer: a case report.
Isogai A; Kotani H; Sawaki M; Hattori M; Yoshimura A; Kataoka A; Nozawa K; Ozaki Y; Endo Y; Nakakami A; Komaki R; Iwata H
Surg Case Rep; 2023 Jun; 9(1):112. PubMed ID: 37341815
[TBL] [Abstract][Full Text] [Related]
36. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
[TBL] [Abstract][Full Text] [Related]
37. The interaction between carcinoembryonic antigen-related cell adhesion molecule 6 and human epidermal growth factor receptor 2 is associated with therapeutic efficacy of trastuzumab in breast cancer.
Iwabuchi E; Miki Y; Kanai A; Miyashita M; Kijima G; Hirakawa H; Suzuki T; Ishida T; Sasano H
J Pathol; 2018 Nov; 246(3):379-389. PubMed ID: 30058236
[TBL] [Abstract][Full Text] [Related]
38. Local-regional control according to surrogate markers of breast cancer subtypes and response to neoadjuvant chemotherapy in breast cancer patients undergoing breast conserving therapy.
Caudle AS; Yu TK; Tucker SL; Bedrosian I; Litton JK; Gonzalez-Angulo AM; Hoffman K; Meric-Bernstam F; Hunt KK; Buchholz TA; Mittendorf EA
Breast Cancer Res; 2012 May; 14(3):R83. PubMed ID: 22621334
[TBL] [Abstract][Full Text] [Related]
39. Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial.
Krop IE; Kim SB; Martin AG; LoRusso PM; Ferrero JM; Badovinac-Crnjevic T; Hoersch S; Smitt M; Wildiers H
Lancet Oncol; 2017 Jun; 18(6):743-754. PubMed ID: 28526538
[TBL] [Abstract][Full Text] [Related]
40. Functional imaging of human epidermal growth factor receptor 2-positive metastatic breast cancer using (64)Cu-DOTA-trastuzumab PET.
Mortimer JE; Bading JR; Colcher DM; Conti PS; Frankel PH; Carroll MI; Tong S; Poku E; Miles JK; Shively JE; Raubitschek AA
J Nucl Med; 2014 Jan; 55(1):23-9. PubMed ID: 24337604
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
